Beckett Wilson Helen, Metcalf McGrath Lindsey
Liverpool John Moores University, United Kingdom.
Liverpool John Moores University, United Kingdom.
Int J Drug Policy. 2023 Dec;122:104220. doi: 10.1016/j.drugpo.2023.104220. Epub 2023 Oct 6.
This paper reports on the first qualitative study to interview people prescribed cannabis in the UK. Cannabis is a class B controlled substance under the 1971 Misuse of Drugs (MoD) Act, but a 2018 change to UK regulations provided for the prescription of cannabis for medical purposes. Relatively few people have been able to access a prescription, despite this policy change. This paper examines their experiences.
Qualitative, semi-structured interviews were conducted with 24 people with a prescription for cannabis, or their carers. Data was analysed using a reflextive thematic analysis approach. The findings are discussed using a zemiology (social harms) perspective which provides a language for critical reflection on the current cannabis policy context.
All participants reported that cannabis had significantly improved their mental and/or physical health, across a broad range of conditions. Many had been able to reduce their use of conventional medicines and reported that cannabis had relatively few side effects. Despite the potentially life-enhancing benefits of cannabis medicine, patients in the UK face multiple barriers to access. These include a lack of funding streams, bureaucratic supply problems, and a lack of training for doctors and police. Even for the few people able to obtain a prescription, the ongoing criminalisation of cannabis in the UK contributed to their experiences of stigmatisation. This often made it difficult and anxiety-inducing to take their medicine in public spaces.
The UK government's lack of implementation of medical cannabis legalisation, combined with their ongoing prohibition position, is producing multiple harms to people who need cannabis medicine. The policy context is perpetuating stigmatising attitudes to cannabis which, as we demonstrate, contribute to social harms. We make recommendations on equality of patient access, and highlight the importance of education and policy change as means of combatting stigma.
本文报道了英国首次针对开具大麻处方者的定性研究。根据1971年《药物滥用法》,大麻属于B类受管制物质,但2018年英国法规的一项变更规定了大麻可用于医疗目的的处方。尽管有这一政策变化,但能够获得处方的人相对较少。本文考察了他们的经历。
对24名持有大麻处方的人或其护理人员进行了定性的半结构化访谈。使用反思性主题分析方法对数据进行了分析。研究结果从病因学(社会危害)角度进行了讨论,该角度为批判性反思当前大麻政策背景提供了一种语言。
所有参与者都报告称,大麻在广泛的病症中显著改善了他们的身心健康。许多人能够减少常规药物的使用,并报告称大麻的副作用相对较少。尽管大麻药物有潜在的改善生活的益处,但英国患者在获取方面面临多重障碍。这些障碍包括资金流不足、官僚主义的供应问题,以及医生和警察缺乏培训。即使对于少数能够获得处方的人来说,英国大麻持续的刑事定罪也导致了他们遭受污名化的经历。这往往使得在公共场所服药变得困难且令人焦虑。
英国政府缺乏对医用大麻合法化的实施,再加上其持续的禁止立场,正在对需要大麻药物的人造成多重伤害。这种政策背景使对大麻的污名化态度长期存在,正如我们所表明的,这些态度导致了社会危害。我们就患者获取的平等性提出了建议,并强调了教育和政策变革作为消除污名化手段的重要性。